Emerging Compounds

First Patient Dosed in Phase 3 Trial of OSA Drug Candidate AD109

The first patient has been dosed in Apnimed's phase 3 study of AD109, a drug candidate for obstructive sleep apnea.

Emerging Compounds

Investigational ORX750 Shows Potential in Treating Narcolepsy

Centessa Pharmaceuticals shared details on its upcoming oral presentation, which will focus on ORX750, a drug in preclinical development for the treatment of narcolepsy and other sleep disorders.

Emerging Compounds

FDA Grants Fast Track Designation to Eli Lilly Diabetes Drug That Might Help People with Obstructive Sleep Apnea Lose Weight

The FDA has granted its Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity or who are overweight with weight-related comorbidities (including obstructive sleep apnea) to facilitate weight loss.

Wakix Hits Record High Prescription Demand in Q2

Aug 2, 2023 | Emerging Compounds, Idiopathic Hypersomnia, Narcolepsy, Prescription Drugs

Harmony Biosciences reported second-quarter business updates, showcasing an upswing in prescription demand for its narcolepsy drug, Wakix.

Narcolepsy Drug Candidate Improves Wakefulness But Raises Liver Concerns

Jul 27, 2023 | Emerging Compounds, Narcolepsy

In a phase 2 trial involving patients with narcolepsy type 1, TAK-994 demonstrated statistically significant improvements in wakefulness and reduced cataplexy rates compared to placebo but was associated with hepatotoxic effects.

Incannex Submits IND for IHL-42X for Sleep Apnea

Jul 21, 2023 | Emerging Compounds, FDA, Obstructive Sleep Apnea

The IND application details the clinical trial protocol for the IND opening clinical trial, which is a multi-site phase 2/3 trial investigating IHL-42X, a cannabinoid combination product, for the treatment of OSA.

Harmony to Begin Phase 3 Study of Pitolisant for Prader-Willi Syndrome

Jul 20, 2023 | Emerging Compounds

The study will further investigate pitolisant in children, adolescents, and adults with Prader-Willi syndrome experiencing excessive daytime sleepiness.

Incannex Taps Fortrea to Manage Phase 2/3 Trial for Sleep Apnea Drug Candidate

Jul 18, 2023 | Emerging Compounds, Obstructive Sleep Apnea, Pharmaceuticals

The phase 2/3 clinical trial will assess the safety and efficacy of IHL-42X, a cannabinoid combination product, in people with OSA who are intolerant, non-compliant, or naïve to CPAP.

Ethics Committee Greenlights Clinical Trial of IHL-42X for Sleep Apnea

Jul 6, 2023 | Emerging Compounds, Obstructive Sleep Apnea

The clinical trial will assess the pharmacokinetics and tolerability of the two active pharmaceutical ingredients in IHL-42X: dronabinol (THC) and acetazolamide.

Phase 3 Trial of Mazindol ER for Narcolepsy to Begin

Jul 6, 2023 | Emerging Compounds, Narcolepsy

The AMAZE program, commencing this summer at multiple sites in the US, will encompass two almost-identical double-blind phase 3 studies investigating mazindol ER versus placebo in adult patients with narcolepsy.

Incannex Enlists Investigators for Phase 2/3 Study of IHL-42X for Sleep Apnea

Jun 16, 2023 | Emerging Compounds, Obstructive Sleep Apnea

IHL-42X, a cannabinoid combination product, is being developed as a pharmacological option for obstructive sleep apnea.

Mazindol Demonstrates Low Risk for Drug Interactions in Narcolepsy Treatment

Jun 15, 2023 | Emerging Compounds, Narcolepsy

Swiss clinical-stage biopharmaceutical company NLS Pharmaceutics Ltd announced positive data from five in vitro drug-drug interaction studies investigating mazindol.

Harmony Announces Positive Phase 2 Data on Pitolisant for Prader-Willi Syndrome

Jun 8, 2023 | Emerging Compounds

Harmony Biosciences presented safety and efficacy data from a phase 2 study evaluating pitolisant for the treatment of excessive daytime sleepiness in people with Prader-Willi syndrome at SLEEP 2023.

Axsome to Present New Sunosi Data at SLEEP 2023

Jun 2, 2023 | Emerging Compounds, Narcolepsy, Obstructive Sleep Apnea, Prescription Drugs

The presentations include data from the SHARP study in patients with excessive daytime sleepiness associated with OSA, real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses.

Category: Emerging Compounds

Emerging Compounds

Emerging Compounds

Emerging Compounds